Cynthia Smith
CIK 1609480 · Chief Commercial Officer · last filed 2026-06-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$899.4K
Companies
7
Total Filings
47
Lifetime Open-Market Net
-$2.5K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SPRO | Director | 85,000 | $1.20 | $101.6K | $0 | 10 | 2026-06-25 |
| AGIO | Director | 15,230 | $35.99 | $548.1K | $0 | 9 | 2026-06-23 |
| AKBA | Director | 196,633 | $1.27 | $249.7K | -$2.5K | 10 | 2026-06-22 |
| TARA | Director | — | $3.94 | — | $0 | 7 | 2026-06-16 |
| TVRD | Director | — | $2.44 | — | $0 | 2 | 2026-06-11 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | Director | 0 | $38.22 | $0 | $0 | 5 | 2021-12-29 |
| ZS Pharma, Inc. (ZSPH) Delisted | Chief Commercial Officer | 9,155 | — | — | $0 | 3 | 2015-12-10 |
Recent Filings · Page 3 of 5
47 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-06-08 | AKBA | Grant (A) | +30,000 | $0 | EDGAR |
| 2023-06-08 | TARA | Grant (A) | — | $0 | EDGAR |
| 2022-09-19 | SPRO | Grant (A) | +15,000 | $0 | EDGAR |
| 2022-08-15 | AGIO | Grant (A) | — | $0 | EDGAR |
| 2022-06-09 | AKBA | Grant (A) | +13,700 | $0 | EDGAR |
| 2022-06-09 | TARA | Grant (A) | — | $0 | EDGAR |
| 2021-12-29 | Dicerna Pharmaceuticals Inc (DRNA) Delisted | Mixed | −3,333 | -$127.5K | EDGAR |
| 2021-08-18 | SPRO | Grant (A) | — | $0 | EDGAR |
| 2021-06-10 | TARA | Grant (A) | — | $0 | EDGAR |
| 2021-06-07 | Dicerna Pharmaceuticals Inc (DRNA) Delisted | Mixed | +3,333 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.